Kevin Antoine Brown

Kevin Antoine Brown

Auto-generated profile, based on publicly available information

Kevin Antoine Brown

Dalla Lana School of Public Health, University of Toronto , Toronto, Ontario

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2013 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
PDF file
KBKevin A. Brown
Kevin A. Brown
NKNagham Khanafer
Nagham Khanafer
NDNick Daneman
Nick Daneman
DFDavid N. Fisman
David N. Fisman
The rising incidence of Clostridium difficile infection (CDI) could be reduced by lowering exposure to high-risk antibiotics. The objective of this study was to determine the association between antibiotic class and the risk of CDI in the community setting. The EMBASE and PubMed databases were queried without restriction to time period or language. Comparative observational studies and randomized controlled trials (RCTs) considering the impact of exposure to antibiotics on CDI risk among nonhospitalized populations were considered. We estimated pooled odds ratios (OR) for antibiotic classes using random-effect meta-analysis. Our search criteria identified 465 articles, of which 7 met inclusion criteria; all were observational studies. Five studies considered antibiotic risk relative to no antibiotic exposure: clindamycin (OR = 16.80; 95% confidence interval [95% CI], 7.48 to 37.76), fluoroquinolones (OR = 5.50; 95% CI, 4.26 to 7.11), and cephalosporins, monobactams, and carbapenems (CMCs) (OR = 5.68; 95% CI, 2.12 to 15.23) had the largest effects, while macrolides (OR = 2.65; 95% CI, 1.92 to 3.64), sulfonamides and trimethoprim (OR = 1.81; 95% CI, 1.34 to 2.43), and penicillins (OR = 2.71; 95% CI, 1.75 to 4.21) had lower associations with CDI. We noted no effect of tetracyclines on CDI risk (OR = 0.92; 95% CI, 0.61 to 1.40). In the community setting, there is substantial variation in the risk of CDI associated with different antimicrobial classes. Avoidance of high-risk antibiotics (such as clindamycin, CMCs, and fluoroquinolones) in favor of lower-risk antibiotics (such as penicillins, macrolides, and tetracyclines) may help reduce the incidence of CDI.

17 February 2022 in JAMA
Verified
Journal Article
Open access
PDF file
AUAna Cecilia Ulloa
Ana Cecilia Ulloa
SBSarah A. Buchan
Sarah A. Buchan
NDNick Daneman
Nick Daneman
KBKevin A. Brown
Kevin A. Brown
The World Health Organization designated Omicron as a variant of concern on November 26, 2021. Omicron has 37 mutations in the spike protein and has rapidly replaced Delta as the dominant variant globally, due to increased immune evasion.1 It is less clear how the severity of Omicron compares with that of Delta. Early data from South Africa suggest that Omicron may be less severe than prior lineages2; however, the low average age of infected individuals, extent of previous infection, and low vaccination rates affect generalizability to certain other countries. In Ontario, Canada, we examined hospitalizations and deaths associated with Omicron compared with matched patients infected with Delta.

2 June 2010 in JAMA
Verified
Journal Article
Closed access
PDF file
LLLaurie Lambert
Laurie Lambert
KBKevin Brown
Kevin Brown
ESEli Segal
Eli Segal
JBJames Brophy
James Brophy
JRJosep Rodes-Cabau
Josep Rodes-Cabau
PBPeter Bogaty
Peter Bogaty
Research from JAMA — Association Between Timeliness of Reperfusion Therapy and Clinical Outcomes in ST-Elevation Myocardial Infarction

1 February 2021 in JAMA Internal Medicine
Verified
Journal Article
Open access
PDF file
KBKevin A. Brown
Kevin A. Brown
AJAaron Jones
Aaron Jones
NDNick Daneman
Nick Daneman
ACAdrienne K. Chan
Adrienne K. Chan
KSKevin L. Schwartz
Kevin L. Schwartz
NSNathan M. Stall
Nathan M. Stall
Nursing home residents have experienced the brunt of the coronavirus disease 2019 (COVID-19) epidemic. Recent estimates suggest that nursing home residents comprise approximately 35% of COVID-19 deaths in the US and between 66% and 81% of deaths in Canada.1,2 Compared with community-dwelling older adults, nursing home residents are 5 times more likely to die of COVID-19.3 The concentration of COVID-19 mortality among nursing home residents can be explained by the high risk of contracting infection because of congregate living, exposure to staff, and difficulties with physically distancing because of cognitive and functional impairment. Residents who acquire infection are at high risk of mortality because of advanced age (immunosenescence) and multimorbidity.4-6

20 April 2022 in Journal of Clinical Microbiology
Verified
Journal Article
Closed access
MVMark Verway
Mark Verway
KBKevin A. Brown
Kevin A. Brown
AMAlex Marchand-Austin
Alex Marchand-Austin
CDChristina Diong
Christina Diong
SLSamantha Lee
Samantha Lee
NDNick Daneman
Nick Daneman
Bloodstream infections (BSIs) represent a substantial mortality risk, yet most studies are limited to select pathogens or populations. The aim of this study was to describe the population-wide prevalence of BSIs and examine the associated mortality risk for the responsible microorganisms.

1 April 2017 in JAMA Internal Medicine
Verified
Journal Article
Closed access
PDF file
VSVanessa W. Stevens
Vanessa W. Stevens
RNRichard E. Nelson
Richard E. Nelson
ESElyse M. Schwab-Daugherty
Elyse M. Schwab-Daugherty
KKKarim Khader
Karim Khader
MJMakoto M. Jones
Makoto M. Jones
MRMichael A. Rubin
Michael A. Rubin
Importance Metronidazole hydrochloride has historically been considered first-line therapy for patients with mild to moderateClostridium difficileinfection (CDI) but is inferior to vancomycin hydrochloride for clinical cure. The choice of therapy may likewise have substantial consequences on other downstream outcomes, such as recurrence and mortality, although these secondary outcomes have been less studied. Objective To evaluate the risk of recurrence and all-cause 30-day mortality among patients receiving metronidazole or vancomycin for the treatment of mild to moderate and severe CDI. Design, Setting, and Participants This retrospective, propensity-matched cohort study evaluated patients treated for CDI, defined as a positive laboratory test result for the presence ofC difficiletoxins or toxin genes in a stool sample, in the US Department of Veterans Affairs health care system from January 1, 2005, through December 31, 2012. Data analysis was performed from February 7, 2015, through November 22, 2016. Exposures Treatment with vancomycin or metronidazole. Main Outcomes and Measures The outcomes of interest in this study were CDI recurrence and all-cause 30-day mortality. Recurrence was defined as a second positive laboratory test result within 8 weeks of the initial CDI diagnosis. All-cause 30-day mortality was defined as death from any cause within 30 days of the initial CDI diagnosis. Results A total of 47 471 patients (mean [SD] age, 68.8 [13.3] years; 1947 women [4.1%] and 45 524 men [95.9%]) developed CDI, were treated with vancomycin or metronidazole, and met criteria for entry into the study. Of 47 147 eligible first treatment episodes, 2068 (4.4%) were with vancomycin. Those 2068 patients were matched to 8069 patients in the metronidazole group for a total of 10 137 included patients. Subcohorts were constructed that comprised 5452 patients with mild to moderate disease and 3130 patients with severe disease. There were no differences in the risk of recurrence between patients treated with vancomycin vs those treated with metronidazole in any of the disease severity cohorts. Among patients in the any severity cohort, those who were treated with vancomycin were less likely to die (adjusted relative risk, 0.86; 95% CI, 0.74 to 0.98; adjusted risk difference, –0.02; 95% CI, –0.03 to –0.01). No significant difference was found in the risk of mortality between treatment groups among patients with mild to moderate CDI, but vancomycin significantly reduced the risk of all-cause 30-day mortality among patients with severe CDI (adjusted relative risk, 0.79; 95% CI, 0.65 to 0.97; adjusted risk difference, –0.04; 95% CI, –0.07 to –0.01). Conclusions and Relevance Recurrence rates were similar among patients treated with vancomycin and metronidazole. However, the risk of 30-day mortality was significantly reduced among patients who received vancomycin. Our findings may further justify the use of vancomycin as initial therapy for severe CDI.